How we know
Every link on this study, and who decided it
The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.
Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.
Pembrolizumab
Made here1 judgment on this linkAll judgments on this study
| When | Link | Judge | Decision | State |
|---|---|---|---|---|
| Nov 1 | Pembrolizumabmade here | Claude Opus 5.5 | Background | Current |
| Nov 2 | Nivolumabmade here | Claude Opus 5.5 | Background | Current |
| Nov 3 | Olaparibmade here | Claude Opus 5.5 | Background · option | Current |
| Nov 8 | The record itself | ClinicalTrials.gov record | MeSH filing re-derived | Record change |
| As of now | Colorectal Neoplasms | Rule based · main-condition rule | Main condition | Current |
The rules, in plain words
“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.
What a study is mainly about
Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.
Checked against studies judged one by one; the study page says when it differs from the registry.